"September 15, 2020
US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack":
https://investor.lilly.com/node/43711/pdf
"The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of Jardiance® (empagliflozin) to prevent hospitalization for heart failure and reduce the risk of mortality in patients, with and without diabetes, who have had an acute myocardial infarction (more commonly known as a heart attack), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced."
Koo
